Clinicopathological characteristics and long-term outcomes of adult patients with proliferative lupus nephritis

Table 3 5-year renal outcomes in patients with and without requirement of kidney replacement therapy on presentation, n (%)

	Overall (n = 207)	Required KRT on presentation (n = 19)	Not required KRT on presentation (n = 188)	P value
Renal outcomes after induction with pulse cyclophosphamide at 6 months
CR	64 (30.9)	2 (10.52)	62 (32.97)	0.04
PR	122 (58.9)	9 (47.36)	113 (60.1)	0.28
ESKD	7 (3.4)	3 (15.7)	4 (2.12)	0.002
Mortality	14 (6.8)	5 (26.3)	9 (4.78)	0.000
Final outcomes at 5 years
CR	94 (45.4)	3 (15.7)	91 (48.40)	0.005
PR	47 (22.7)	2 (10.52)	45 (23.9)	0.170
ESKD	38 (18.35)	8 (42.10)	30 (15.95)	0.010
Mortality	28 (13.52)	6 (31.57)	22 (11.7)	0.016
Renal relapses during 5-year follow-up	34 (16.4)	0	34 (18.0)	0.043
Azathioprine	30 (88.2)	0	30 (88.2)
Mycophenolate mofetil	4 (11.76)		4 (11.76)
Re-biopsy	23 (11.1)	1 (5.2)	22 (11.70)	0.67

CR: Complete remission; ESKD: End-stage kidney disease; KRT: Kidney replacement therapy; PR: Partial remission.